Trial Profile
Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary) ; Methotrexate (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- 05 Oct 2021 Status changed from completed to discontinued.
- 16 Dec 2020 Status changed from recruiting to completed.
- 24 May 2012 Company (Serono Europe) added to the associations field as reported by European Clinical Trials Database record.